Lund's embryonic-stem-cell dopamine recipe

The research record

This is the project's file for this landmark, as written and checked. Sources are listed at the end; anything not yet confirmed is marked "Not yet verified".

Who

Agnete Kirkeby, Malin Parmar and colleagues at Lund University. Olle Lindvall co-authored the 2012 paper; Stephen Dunnett and Thomas Perlmann (Karolinska Institutet) co-authored the 2017 paper. The STEM-PD trial that followed is funded by a grant from Novo Nordisk A/S, and Parmar and Kirkeby both report paid consultancy for Novo Nordisk (trial-protocol paper, BMJ Open 2025); Parmar is a co-inventor on patents, whose content was not checked.

What happened

In 2012 (Cell Reports) the team added a small molecule that activates one signalling pathway (WNT), at different doses, to make progenitors for different brain regions under defined conditions. Midbrain-patterned cells grafted into rats formed neuron-rich grafts without tumours, made authentic dopamine neurons that matched fetal midbrain cells, released dopamine and reversed motor deficits in a Parkinson's rat model. Cells patterned to other regions did not.

In 2016–17 (Cell Stem Cell, online 27 Oct 2016, print 2017) they analysed more than 30 batches of embryonic-stem-cell-derived progenitors grafted into animals. Many commonly used markers did not predict how well cells matured; a set of caudal midbrain markers did predict dopamine-neuron yield. The team used them to build a GMP (clinical-grade manufacturing) protocol that was efficient and reproducible.

Why it moved us toward a cure

It solved a practical problem of cell therapy: not just making dopamine neurons (landmark 17) but making them consistently, with a quality test before surgery. That is what the failed fetal grafts lacked (landmark 3).

Outcome

Advanced. Lund went on to run its own trial (landmark 74), using cells from the RC17 embryonic line made under GMP; the product's quality and safety data are in Kirkeby 2023. That the trial product follows exactly the 2017 protocol is likely but not confirmed by a source read. The cell recipe is separate from the Memorial Sloan Kettering/BlueRock product in landmark 10.

Sources

• Kirkeby et al., Cell Reports 2012;1(6):703–714, DOI 10.1016/j.celrep.2012.04.009, PubMed 22813745
• Kirkeby et al., Cell Stem Cell 2017;20(1):135–148, DOI 10.1016/j.stem.2016.09.004, PubMed 28094017
• Kirkeby et al., Cell Stem Cell 2023;30:1299–1314, DOI 10.1016/j.stem.2023.08.014, PubMed 37802036 (STEM-PD preclinical package)
• Paul et al., STEM-PD trial protocol, BMJ Open 2025;15:e107597, PMC12766818 (funding and disclosures)
• Neuroscience News on the 2016 release (online date, Lund/Karolinska roles)
• Checked 19 Oct 2026: Europe PMC lists no erratum or retraction for the 2012 or 2017 papers.
• Not yet verified: that the STEM-PD product uses exactly the 2017 protocol; what the Parmar patents cover.